Palliative Radiotherapy of Primary Glioblastoma
| Autor: | Jaspar Witteler, Dirk Rades, Steven E. Schild |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty medicine.medical_treatment Complete resection General Biochemistry Genetics and Molecular Biology Palliative radiotherapy Survival prognosis Internal medicine Biopsy Temozolomide medicine Humans Antineoplastic Agents Alkylating Retrospective Studies Pharmacology Primary Glioblastoma medicine.diagnostic_test Brain Neoplasms business.industry Prognosis Incomplete Resection Radiation therapy Glioblastoma business Research Article medicine.drug |
| Zdroj: | In Vivo |
| ISSN: | 1791-7549 0258-851X |
| Popis: | Background/aim Care is often palliative when patients are not fit and complete resection of glioblastomas cannot be achieved. This study aimed to identify predictors of survival after palliative radiotherapy. Patients and methods Thirty-one patients irradiated after biopsy or incomplete resection of primary glioblastoma were retrospectively analyzed. Median total dose, dose per fraction and equivalent dose in 2 Gy fractions (EQD2) were 45.0 Gy, 3.0 Gy and 46.0 Gy, respectively. Median number of fractions was 15, median treatment time 3 weeks. Ten patients received temozolomide. Six factors were evaluated for survival including location of glioblastoma, Karnofsky performance score (KPS), gender, age, EQD2 and temozolomide. Results KPS ≥60 showed a trend for improved survival (p=0.141). For other factors including EQD2, no significant association with survival was found. Conclusion Patients with a KPS ≤50 have a poor survival prognosis and appear good candidates for short-course radiotherapy. Selected patients with better KPS may be considered for more aggressive treatments. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|